Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Asenapina

Sycrest

Bibliografia - Quali fonti bibliografiche per Asenapina?

  1. Agenzia Italiana del Farmaco - AIFA, 2014 - Sycrest, Riassunto della caratteristiche del prodotto, disponibile online https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000764_040761_RCP.pdf&retry=0&sys=m0b1l3 (accesso Aprile 2014).

  2. Caccia S., Curr. Opin. Investig. Drugs., 2002, 3 (7), 1073.

  3. Caccia S., Expert Opin. Drug Metab. Toxicol., 2011, 7 (7), 829.

  4. Calabrese J. et al., Eur. Psychiatry, 2010, 25 (Suppl 1), 1447.

  5. Citrome L., Int. J. Clin. Pract., 2009, 63 (12), 1762.

  6. Citrome L., Expert Opin. Drug Saf., 2014a, 13 (6), 803.

  7. Citrome L., Expert Opin. Drug Metab. Toxicol., 2014b, 10 (6), 893.

  8. European Medicine Agency - EMA, 2010 - Sycrest, Riassunto della caratteristiche del prodotto, disponibile online http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/001177/ WC500096895.pdf (accesso Aprile 2014).

  9. Food and Drug Administration – FDA, Drug Safety Communication, 2011, 1 settembre disponible online http://www.fda.gov/Drugs/DrugSafety/ucm270243.htm

  10. Food and Drug Administration – FDA, Drug Dvelopment and drug Interactions, 2011a, disponibile online http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm

  11. Food and Drug Administration – FDA, SAPHRIS® Label Information, 2013, disponibile online http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo (accesso agosto 2014)

  12. Funke C.W. et al., Arzneimittelforschung, 1990, 40 (5), 536.

  13. Kane J.M. et al., J. Clin. Psychiatr,y 2011, 72, 349.

  14. Lundbeck Canada Inc. SAPHRIS® Product information, revised May 31, 2013, disponibile online www.Lundbeck.com/upload/ca/en/files/pdf/pm/SAPHRIS.pdf (accesso Aprile 2014).

  15. McIntyre R.S. et al., Bipolar Disord., 2009a, 11 (7), 673.

  16. McIntyre R.S. et al., Bipolar Disord., 2009b, 11 (8), 815.

  17. McIntyre R.S. et al., J. Affect. Disord., 2010a, 122 (1-2), 27.

  18. McIntyre R.S. et al., J. Affect. Disord., 2010b, 126 (3), 358.

  19. Minassian A., Young J.W., Expert Opin. Pharmacother., 2010, 11 (12), 2107.

  20. Potkin S.G., J. Clin. Psychiatry, 2011, 72 (Suppl 1), 14.

  21. Schoemaker J. et al., Pharmacopsychiatry, 2010, 43 (4), 138.

  22. Spina E., de Leon J., Expert Opin. Drug Metab. Toxicol., 2014, 10 (5):721.

  23. Stoner S.C., Pace H.A., Clin. Ther., 2012, 34 (5).